Coronary Artery Bypass is surgery in which a healthy blood vessel taken from another part of the body is used to make a new path for blood around a blocked artery leading to the heart. This restores the flow of oxygen and nutrients to the heart. Also called aortocoronary bypass and CAB.
Use of MC-1 (a naturally occurring metabolite of vitamin B6) before and for 30 days after coronary artery bypass graft surgery did not reduce the risk of heart attack or cardiovascular death, according to a JAMA study being released early online April 1 to coincide with its presentation at the annual conference of the American College of Cardiology.
The largest study to date of a controversial cardiac surgery drug shows it increases death rates and damages kidney function, according Duke University Medical Center researchers.
Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).
The Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.
A Czech study compared two anti-clotting treatment regimens, currently used before coronary angiography / angioplasty to find the optimal balance between preventing ischemic versus bleeding complications of these procedures. The study was conducted in five Czech tertiary cardiology centers.
A new study suggests that patients undergoing coronary artery bypass surgery may have improved outcomes by having a procedure done that temporarily restricts the blood flow in their arm.
Schering-Plough Corporation has announced the worldwide licensing of acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA), from PeriCor Therapeutics, Inc., a privately held, specialty biopharmaceutical company.
A new study on the outcome of cardiac surgery in patients with liver cirrhosis found that the surgery can safely be performed in patients with milder disease, while those with more severe cirrhosis are less likely to survive.
By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.
The test, developed in the study by the researchers, is a 14-point index combining medical history, cognitive testing, and physical examination. It requires no special equipment and can be given in a clinical setting such as a doctor's office or at a patient's bedside.
Patients whose mean arterial blood pressure drops during bypass surgery may be at risk for early difficulties in thinking, learning and memory, according to an article posted online today that will appear in the August 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.
Rheumatoid arthritis, lupus, and other inflammatory rheumatic diseases are associated with a high rate of death from heart disease.
Coronary artery bypass surgery has been the preferred treatment for patients with a blockage in the left main coronary artery, the conduit that supplies blood to about two-thirds of the heart.
Duke University Medical Center researchers believe their findings could help physicians identify patients at risk of suffering mental decline after heart surgery and raises the possibility that these patients could be treated with drugs that are known to dampen the inflammatory response.
The findings are based on almost 26,000 patients who had coronary artery bypass surgery (CABG) for the first time between1997 to 2005, in the north west of England.
Patients who receive corticosteroids after cardiac surgery have a significantly lower risk of atrial fibrillation in the days following the surgery, according to a study in the April 11 issue of JAMA.
Heart surgeons don't have to choose between taking a coronary-bypass patient off the popular anti-clotting drug clopidogrel (Plavix) after off-pump heart bypass surgery or having the patient bleed excessively in the days following surgery, according to a new study by researchers at Jefferson Medical College.
Aprotinin, a drug used for limiting blood loss in patients undergoing cardiac surgery, is associated with an increased risk of death during five years following the surgery, according to a new study in the February 7 issue of JAMA: The Journal of the American Medical Association.
The incidence of kidney damage associated with coronary artery bypass surgery has increased significantly over the past 16 years in the United States, but the rate of death from such damage has decreased significantly during the period, according to a new analysis.
Medication, angioplasty or surgery? For some heart disease patients, there's no clear-cut choice. The key to getting the best care is to follow your individual doctor's advice, new research shows.